What investors need to know

Choreograph (Konstantin Yuganov) | Istock | Getty Images The IRS has released the 2027 contribution limits for health savings accounts, or HSAs, which offer triple-tax benefits for investors. Starting in 2027, the new HSA contribution limit will be $4,500 for self-only plans, up from $4,400 in 2026, based on the latest inflation adjustments. The HSA limit for…

Read More

Supreme Court ruling on deportation protections is ‘bad news’ for every TPS recipient

The Supreme Court’s decision ending deportation protections for Haitians and Syrians is causing trouble for all recipients of Temporary Protected Status (TPS), regardless of their home country. The Trump administration is cutting TPS, the status former governments granted to citizens of 17 countries after determining it would not be safe to deport them… Source link

Read More

Rosen accuses Moreno of snooping on staff's cars

What started as a Senate Commerce Committee hearing on transportation nominees turned into a verbal confrontation between senators. jackie rosen (D-Nev.) and Bernie Moreno (R-Ohio), the former accused the latter of spying on him and his staff. Moreno, President Trump’s nominee for Under Secretary of Transportation for Policy, being questioned by Ryan McCormack Said He…

Read More

Brennan on reported DOJ scrutiny: 'I've had no contact'

Former CIA director John Brainon on Wednesday commented on the investigation faced by the Justice Department (DOJ), stating that he had “no contact” with federal officials. Washington Post Informed on Wednesday DOJ Saud’s former FBI directors James Comi and Brainon were facing a “criminal investigation”. “I don’t know if anyone is there or not, you…

Read More

What’s next for the weight loss drug maker

Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher patient dropout rates than leading treatments, prompting analysts to slash peak sales forecasts and rethink the company’s obesity strategy. But while the market’s enthusiasm for the drug has meaningfully cooled, investors are shifting focus to…

Read More